Navigation Links
Entest Biomedical Enters into Discussions with Laser Manufacturer to Develop Proprietary Photoceutical Device for COPD Treatment
Date:11/24/2009

Laser-type device to be coupled with Stem Cell Therapy.

San Diego, CA (PRWEB) November 24, 2009 -- Entest Biomedical, Inc. (OTCBB: ENTB) announced that it has initiated discussions with a manufacturer of lasers regarding the development of a proprietary laser device which shall be owned by Entest and used in conjunction with several stem cell therapies currently being developed by Entest. These therapies are aimed at increasing efficacy in treating Chronic Obstructive Pulmonary Disease (COPD). A spokesman for Entest stated that this particular manufacturer was approached due to their success in commercializing medical devices in the North American market.

“Biotechnology R&D companies like Entest frequently have intellectual property tied to medical devices under development. Entest’s planned usage of laser-type devices in treating COPD requires the adaptation of current laser technology into a device that supports the Company’s Stem Cell / Photoceutical therapy.” said David Koos, Chairman and CEO of Entest. “Companies such as PhotoThera in Carlsbad, California, have successfully used this approach in developing their laser-based NeurotheraÒ technology for treating ischemic stroke patients (currently in Phase III clinical trials).”

Entest’s patent-pending approach revolves around the use of the patient’s own stem cells in combination with specific laser wavelengths to repair damaged lung tissue of patients with COPD.

Ernest’s goal is the generation of schematics, code, and intellectual property pertaining to the new device which will serve as the basis for regulatory filings and FDA development of the Entest “regenerative photoceutical” approach to COPD.

About Entest BioMedical Inc.:

Entest BioMedical Inc. (OTCBB: ENTB) is a majority owned subsidiary of Bio-Matrix Scientific Group Inc (OTCBB: BMSN). The Company is involved with the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), immuno-cancer therapies, testing procedures for diabetes, stem cell research applications for diabetes and other illnesses. The Company also is involved with medical device development (including stem cell extraction instrumentation).

Disclaimer

This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact:

David R. Koos, Chairman & CEO
619.702.1404 Direct
619.330.2328 Fax

Entest BioMedical Inc.
www.EntestBio.com

###

Read the full story at http://www.prweb.com/releases/Entest_Biomedical/laser_device_COPD/prweb3253704.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Entest BioMedical Files 3rd Patent Application for COPD Stem Cell Treatment
2. Entest BioMedical, Inc. Discusses How Therapies in Development May Yield Lucrative Revenue Streams for the Company
3. Entest BioMedical Inc. Adds Former National Cancer Institute Researcher to Scientific Advisory Board With Focus on Stem Cell Cancer Patient Therapies
4. Bio-Matrix Scientific Group and Entest BioMedical Sign Contract With UCLA Researcher to Develop Gestational Diabetes Screening Test
5. Largest British Fund for Biomedical Research Finances Project on Breakbone Fever in Leuven (K.U.Leuven)
6. Biomedical Research Centre searches for immunological biomarkers
7. Nine International Research Teams Collaborate to Successfully Operate Multiple Biomedical Robots from Numerous Locations
8. Sponsor-A-Scientist: New Option to Fund Biomedical Research
9. Biomedical Research Centre developing enhanced cells as therapies
10. Environmental Tectonics Corporations BioMedical Systems Division Announces First BARA-MED(R) Monoplace Hyperbaric Chamber Sale in Romania
11. New test for safer biomedical research results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... City, Colo. (PRWEB) , ... April 21, 2017 , ... ... of the Flex House, the next project in the company’s esteemed VISION House demonstration ... help homeowners use exactly the amount of resources they need to live affordably and ...
(Date:4/21/2017)... ... April 21, 2017 , ... The Hong Kong Polytechnic University ... printing facility among higher education institutions in Hong Kong to support teaching, learning and ... the range and quantity of facilities in Hong Kong. , With an area ...
(Date:4/21/2017)... ... ... Alive for Wellness is a group of clinical professionals and ... Alive team uses advanced behavioral sciences treatment modalities to accomplish their goals. ... struggle is based on 10 modalities of treatment that include: , ...
(Date:4/21/2017)... Malvern, Worcestershire, UK (PRWEB) , ... April 21, ... ... Queen’s Award for Enterprise in the category of International Trade, the UK’s most ... performance in international trade, which represents 95% of total revenues and has grown ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... BrightStar Care ... partnered with Advanced Patient Care of Utah (APCUT) and has appointed Rex Wheeler as ... next chapter of growth for our agency and our ability to provide quality care ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Ind. , April 20, 2017  Zimmer Biomet ... in musculoskeletal healthcare, today announced that it will be ... Care Conference at the InterContinental Hotel in ... Zimmer Biomet will present at 11:20 a.m. Eastern Time. ... be accessed via Zimmer Biomet,s Investor Relations website at ...
(Date:4/20/2017)... April 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: ... that address significant unmet medical needs, today announced ... Company,s consumer product development program, based on its ... for Investigative Dermatology (SID) 76 th Annual ... promote the sciences relevant to skin health and ...
(Date:4/20/2017)... April 20, 2017  CVS Pharmacy, the retail ... a new store design to enhance the retail ... food, health-focused products and expanded beauty selections paired ... customers discover new offerings. Together with its innovative ... of the customer experience at CVS Pharmacy.  ...
Breaking Medicine Technology: